Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
03
2021
accepted:
13
05
2021
revised:
29
04
2021
pubmed:
4
6
2021
medline:
22
12
2021
entrez:
3
6
2021
Statut:
ppublish
Résumé
Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK dysregulation have been identified, resulting in multiple cancer types displaying 'oncogenic addiction' to RTKs. As a result, RTKs have represented a major class for targeted therapeutics over the past two decades, with numerous small molecule-based tyrosine kinase inhibitor (TKI) therapeutics having been developed and clinically approved for several cancers. However, many of the current RTK inhibitor treatments eventually result in the rapid development of acquired resistance and subsequent tumor relapse. Recent technological advances and tools are being generated for the identification of novel RTK small molecule therapeutics. These newer technologies will be important for the identification of diverse types of RTK inhibitors, targeting both the receptors themselves as well as key cellular factors that play important roles in the RTK signaling cascade.
Identifiants
pubmed: 34079087
doi: 10.1038/s41388-021-01841-2
pii: 10.1038/s41388-021-01841-2
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Tyrosine
42HK56048U
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4079-4093Références
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.
pubmed: 20602996
pmcid: 2914105
doi: 10.1016/j.cell.2010.06.011
Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–37.
pubmed: 19269363
pmcid: 2894612
doi: 10.1016/j.cell.2009.02.024
Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58.
pubmed: 29455648
pmcid: 5817791
doi: 10.1186/s12943-018-0782-4
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.
pubmed: 24120142
pmcid: 3910500
doi: 10.1016/j.cell.2013.09.034
Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18:1027–33.
pubmed: 15920544
doi: 10.1038/modpathol.3800438
Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 2009;69:8341–8.
pubmed: 19826035
pmcid: 2783286
doi: 10.1158/0008-5472.CAN-09-2477
Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18:341–58.
pubmed: 29674709
doi: 10.1038/s41568-018-0002-y
Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019;16:105–22.
pubmed: 30367139
doi: 10.1038/s41571-018-0115-y
Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33–48.
pubmed: 31548601
doi: 10.1038/s41571-019-0268-3
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347–61.
pubmed: 12726861
doi: 10.1016/S1535-6108(03)00085-0
Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529:110–4.
pubmed: 26700815
doi: 10.1038/nature16490
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11:217–27.
pubmed: 17349580
pmcid: 1939942
doi: 10.1016/j.ccr.2006.12.017
Tamirat MZ, Koivu M, Elenius K, Johnson MS. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation. PLoS ONE. 2019;14:e0222814.
pubmed: 31536605
pmcid: 6752865
doi: 10.1371/journal.pone.0222814
Foster SA, Whalen DM, Ozen A, Wongchenko MJ, Yin J, Yen I, et al. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell. 2016;29:477–93.
pubmed: 26996308
doi: 10.1016/j.ccell.2016.02.010
Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280:5350–70.
pubmed: 23777544
doi: 10.1111/febs.12393
Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14:173–86.
pubmed: 24561444
doi: 10.1038/nrc3680
Songyang Z, Carraway KL, Eckt MJ, Harrison SC, Feldman§ RA, Mohammadi M, et al. Catalytic specificity of proteintyrosine kinases is critical for selective signalling. Nature. 1995;373:536–9.
pubmed: 7845468
doi: 10.1038/373536a0
Gujral TS, Singh VK, Jia Z, Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res. 2006;66:10741–9.
pubmed: 17108110
doi: 10.1158/0008-5472.CAN-06-3329
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.
pubmed: 30651634
pmcid: 6365380
doi: 10.1038/s41375-018-0357-9
Griffith J, Black J, Faerman C, Swenson L, Wynn M, Fan LU, et al. The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain. Mol Cell. 2004;13:169–78.
pubmed: 14759363
doi: 10.1016/S1097-2765(03)00505-7
Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26:47–51.
pubmed: 31932802
doi: 10.1038/s41591-019-0716-8
Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36:326–39.
pubmed: 19854140
doi: 10.1016/j.molcel.2009.09.019
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.
pubmed: 17625570
doi: 10.1038/nature05945
Ducray SP, Natarajan K, Garland GD, Turner SD, Egger G. The transcriptional roles of ALK fusion proteins in tumorigenesis. Cancers (Basel). 2019;11:1074.
doi: 10.3390/cancers11081074
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–47.
pubmed: 30333516
pmcid: 6419506
doi: 10.1038/s41571-018-0113-0
Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, et al. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. PNAS. 2003;100:916–21.
pubmed: 12538861
doi: 10.1073/pnas.242741799
Mak HH, Peschard P, Lin T, Naujokas MA, Zuo D, Park M. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene. 2007;26:7213–21.
pubmed: 17533376
doi: 10.1038/sj.onc.1210522
Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337:1231–5.
pubmed: 22837387
pmcid: 3677224
doi: 10.1126/science.1220834
International Cancer Genome Consortium PedBrain Tumor P. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 2016;22:1314–20.
doi: 10.1038/nm.4204
Molhoek KR, Shada AL, Smolkin M, Chowbina S, Papin J, Brautigan DL, et al. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res. 2011;21:274–84.
pubmed: 21654344
pmcid: 3131461
doi: 10.1097/CMR.0b013e328343a1d6
Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18:1118–22.
pubmed: 22683780
pmcid: 3438345
doi: 10.1038/nm.2819
Im JH, Buzzelli JN, Jones K, Franchini F, Gordon-Weeks A, Markelc B, et al. FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nat Commun. 2020;11:4064.
pubmed: 32792542
pmcid: 7426415
doi: 10.1038/s41467-020-17914-x
Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.
pubmed: 12778165
doi: 10.1038/nm0603-669
Tejada ML, Yu L, Dong J, Jung K, Meng G, Peale FV, et al. Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res. 2006;12:2676–88.
pubmed: 16675559
doi: 10.1158/1078-0432.CCR-05-1770
Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLOS Med. 2008;5:e19.
pubmed: 18232728
pmcid: 2214790
doi: 10.1371/journal.pmed.0050019
Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell. 2016;165:910–20.
pubmed: 27087446
pmcid: 4868820
doi: 10.1016/j.cell.2016.03.029
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479–87.
pubmed: 19010923
doi: 10.1158/0008-5472.CAN-08-1643
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–4.
pubmed: 22763439
pmcid: 3711467
doi: 10.1038/nature11183
Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Disco. 2012;2:948–59.
doi: 10.1158/2159-8290.CD-12-0237
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77–88.
pubmed: 20129249
pmcid: 2980857
doi: 10.1016/j.ccr.2009.11.022
Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, et al. Paracrine effect of NRG1 and HGF drives resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res. 2015;75:2737–48.
pubmed: 25952648
pmcid: 4490069
doi: 10.1158/0008-5472.CAN-15-0370
Chi-hong BC, Chernis GA, Van Hoang Q, Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. PNAS. 2003;100:9226–31.
doi: 10.1073/pnas.1332660100
Esposito CL, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A, et al. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE. 2011;6:e24071.
pubmed: 21915281
pmcid: 3167817
doi: 10.1371/journal.pone.0024071
Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharm Res Perspect. 2019;7:e00535.
doi: 10.1002/prp2.535
Bhullar KS, Lagaron NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48.
pubmed: 29455673
pmcid: 5817855
doi: 10.1186/s12943-018-0804-2
Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal. 2013;6:re6.
pubmed: 24065147
doi: 10.1126/scisignal.2004652
Petschnigg J, Groisman B, Kotlyar M, Taipale M, Zheng Y, Kurat CF, et al. The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. Nat Methods. 2014;11:585–92.
pubmed: 24658140
doi: 10.1038/nmeth.2895
Saraon P, Snider J, Kalaidzidis Y, Wybenga-Groot LE, Weiss K, Rai A, et al. A drug discovery platform to identify compounds that inhibit EGFR triple mutants. Nat Chem Biol. 2020;16:577–86.
pubmed: 32094923
pmcid: 8123931
doi: 10.1038/s41589-020-0484-2
Petschnigg J, Kotlyar M, Blair L, Jurisica I, Stagljar I, Ketteler R. Systematic Identification of Oncogenic EGFR Interaction Partners. J Mol Biol. 2017;429:280–94.
pubmed: 27956147
pmcid: 5240790
doi: 10.1016/j.jmb.2016.12.006
Yao Z, Darowski K, St-Denis N, Wong V, Offensperger F, Villedieu A, et al. A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome. Mol Cell. 2017;65:347–60.
pubmed: 28065597
pmcid: 5663465
doi: 10.1016/j.molcel.2016.12.004
Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100–22.
pubmed: 25101824
doi: 10.1038/nprot.2014.138
Molina DM, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84–7.
doi: 10.1126/science.1233606
Perrin J, Werner T, Kurzawa N, Rutkowska A, Childs DD, Kalxdorf M, et al. Identifying drug targets in tissues and whole blood with thermal-shift profiling. Nat Biotechnol. 2020;38:303–8.
pubmed: 31959954
doi: 10.1038/s41587-019-0388-4
Henderson MJ, Holbert MA, Simeonov A, Kallal LA. High-throughput cellular thermal shift assays in research and drug discovery. SLAS Disco. 2020;25:137–47.
doi: 10.1177/2472555219877183
Savitski MM, Reinhard FB, Franken H, Werner T, Savitski MF, Eberhard D, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014;346:1255784.
pubmed: 25278616
doi: 10.1126/science.1255784
Savitski MM, Zinn N, Faelth-Savitski M, Poeckel D, Gade S, Becher I, et al. Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis. Cell. 2018;173:260–274 e225.
pubmed: 29551266
pmcid: 5871718
doi: 10.1016/j.cell.2018.02.030
Alshareef A, Zhang HF, Huang YH, Wu C, Zhang JD, Wang P, et al. The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers. Sci Rep. 2016;6:33710.
pubmed: 27641368
pmcid: 5027386
doi: 10.1038/srep33710
Dart ML, Machleidt T, Jost E, Schwinn MK, Robers MB, Shi C, et al. Homogeneous assay for target engagement utilizing bioluminescent thermal shift. ACS Med Chem Lett. 2018;9:546–51.
pubmed: 29937980
pmcid: 6004564
doi: 10.1021/acsmedchemlett.8b00081
Kobayashi H, Picard LP, Schonegge AM, Bouvier M. Bioluminescence resonance energy transfer-based imaging of protein-protein interactions in living cells. Nat Protoc. 2019;14:1084–107.
pubmed: 30911173
doi: 10.1038/s41596-019-0129-7
Machleidt T, Woodroofe CC, Schwinn MK, Mendez J, Robers MB, Zimmerman K, et al. NanoBRET-A Novel BRET Platform for the Analysis of Protein-Protein Interactions. ACS Chem Biol. 2015;10:1797–804.
pubmed: 26006698
doi: 10.1021/acschembio.5b00143
Macdonald-Obermann JL, Pike LJ. Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. J Biol Chem. 2014;289:26178–88.
pubmed: 25086039
pmcid: 4176247
doi: 10.1074/jbc.M114.586826
Kilpatrick LE, Friedman-Ohana R, Alcobia DC, Riching K, Peach CJ, Wheal AJ, et al. Real-time analysis of the binding of fluorescent VEGF165a to VEGFR2 in living cells: effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes. Biochem Pharm. 2017;136:62–75.
pubmed: 28392095
doi: 10.1016/j.bcp.2017.04.006
Stoddart LA, Kilpatrick LE, Hill SJ. NanoBRET Approaches to Study Ligand Binding to GPCRs and RTKs. Trends Pharm Sci. 2018;39:136–47.
pubmed: 29132917
doi: 10.1016/j.tips.2017.10.006
Macdonald JL, Pike LJ. Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system. Proc Natl Acad Sci USA. 2008;104:20147–8.
De Meyts P. Insulin/receptor binding: the last piece of the puzzle? What recent progress on the structure of the insulin/receptor complex tells us (or not) about negative cooperativity and activation. Bioessays. 2015;37:389–97.
pubmed: 25630923
doi: 10.1002/bies.201400190
Burslem GM, Crews CM. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell. 2020;181:102–14.
pubmed: 31955850
pmcid: 7319047
doi: 10.1016/j.cell.2019.11.031
Paiva SL, Crews CM. Targeted protein degradation: elements of PROTAC design. Curr Opin Chem Biol. 2019;50:111–9.
pubmed: 31004963
pmcid: 6930012
doi: 10.1016/j.cbpa.2019.02.022
Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Deshaies RJ. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. PNAS. 2001;98:8554–9.
pubmed: 11438690
doi: 10.1073/pnas.141230798
Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Disco. 2019;18:949–63.
doi: 10.1038/s41573-019-0047-y
Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11:611–7.
pubmed: 26075522
pmcid: 4629852
doi: 10.1038/nchembio.1858
Bondeson DP, Smith BE, Burslem GM, Buhimschi AD, Hines J, Jaime-Figueroa S, et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol. 2018;25:78–87 e75.
pubmed: 29129718
doi: 10.1016/j.chembiol.2017.09.010
Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, et al. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Res. 2019;79:4744–53.
pubmed: 31311809
pmcid: 6893872
doi: 10.1158/0008-5472.CAN-19-1236
Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, et al. The Advantages of Targeted Protein Degradation Over Inhibition: an RTK Case Study. Cell Chem Biol. 2018;25:67–77 e63.
pubmed: 29129716
doi: 10.1016/j.chembiol.2017.09.009
Burslem GM, Song J, Chen X, Hines J, Crews CM. Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion. J Am Chem Soc. 2018;140:16428–32.
pubmed: 30427680
doi: 10.1021/jacs.8b10320
Cromm PM, Samarasinghe KTG, Hines J, Crews CM. Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation. J Am Chem Soc. 2018;140:17019–26.
pubmed: 30444612
doi: 10.1021/jacs.8b08008
Salami J, Alabi S, Willard RR, Vitale NJ, Wang J, Dong H, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018;1:100.
pubmed: 30271980
pmcid: 6123676
doi: 10.1038/s42003-018-0105-8
Zhao Q, Ouyang X, Wan X, Gajiwala KS, Kath JC, Jones LH, et al. Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes. J Am Chem Soc. 2017;139:680–5.
pubmed: 28051857
pmcid: 5858558
doi: 10.1021/jacs.6b08536
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560–2.
pubmed: 25939061
pmcid: 4771182
doi: 10.1038/nm.3854
Zhao P, Yao MY, Zhu SJ, Chen JY, Yun CH. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045. Biochem Biophys Res Commun. 2018;502:332–7.
pubmed: 29802850
doi: 10.1016/j.bbrc.2018.05.154
Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534:129–32.
pubmed: 27251290
pmcid: 4929832
doi: 10.1038/nature17960
To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Disco. 2019;9:926–43.
doi: 10.1158/2159-8290.CD-18-0903
Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013;5:a016949.
pubmed: 24296170
pmcid: 3839607
doi: 10.1101/cshperspect.a016949
Villasenor R, Nonaka H, Del Conte-Zerial P, Kalaidzidis Y, Zerial M. Regulation of EGFR signal transduction by analogue-to-digital conversion in endosomes. Elife. 2015;4:e06156.
pmcid: 4384751
doi: 10.7554/eLife.06156
Goh LK, Sorkin A. Endocytosis of receptor tyrosine kinases. Cold Spring Harb Perspect Biol. 2013;5:a017459.
pubmed: 23637288
pmcid: 3632065
doi: 10.1101/cshperspect.a017459
Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol. 2009;10:609–22.
pubmed: 19696798
pmcid: 2895425
doi: 10.1038/nrm2748
Rosendale M, Van TNN, Grillo-Bosch D, Sposini S, Claverie L, Gauthereau I, et al. Functional recruitment of dynamin requires multimeric interactions for efficient endocytosis. Nat Commun. 2019;10:4462.
pubmed: 31575863
pmcid: 6773865
doi: 10.1038/s41467-019-12434-9
Villasenor R, Kalaidzidis Y, Zerial M. Signal processing by the endosomal system. Curr Opin Cell Biol. 2016;39:53–60.
pubmed: 26921695
doi: 10.1016/j.ceb.2016.02.002
Chung BM, Raja SM, Clubb RJ, Tu C, George M, Band V, et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol. 2009;10:84.
pubmed: 19948031
pmcid: 2790444
doi: 10.1186/1471-2121-10-84
Joffre C, Barrow R, Menard L, Calleja V, Hart IR, Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol. 2011;13:827–37.
pubmed: 21642981
doi: 10.1038/ncb2257
Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene. 2007;26:6968–78.
pubmed: 17486068
doi: 10.1038/sj.onc.1210503
Robertson MJ, Deane FM, Stahlschmidt W, von Kleist L, Haucke V, Robinson PJ, et al. Synthesis of the Pitstop family of clathrin inhibitors. Nat Protoc. 2014;9:1592–606.
pubmed: 24922269
doi: 10.1038/nprot.2014.106
von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell. 2011;146:471–84.
doi: 10.1016/j.cell.2011.06.025
Menard L, Floc’h N, Martin MJ, Cross DAE. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018;78:3267–79.
pubmed: 29555874
doi: 10.1158/0008-5472.CAN-17-2195
Heldin J, Sander MR, Leino M, Thomsson S, Lennartsson J, Soderberg O. Dynamin inhibitors impair platelet-derived growth factor beta-receptor dimerization and signaling. Exp Cell Res. 2019;380:69–79.
pubmed: 30970237
doi: 10.1016/j.yexcr.2019.04.004
Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006;10:839–50.
pubmed: 16740485
doi: 10.1016/j.devcel.2006.04.002
Orcl L, Tagaya M, Amherdt M, Perrelet A, Donaldson JG, Lippincott-Schwartz J, et al. Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. Cell. 1991;64:1183–95.
doi: 10.1016/0092-8674(91)90273-2
Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, et al. M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers. Cancer Res. 2016;76:3895–903.
pubmed: 27197184
doi: 10.1158/0008-5472.CAN-15-2220
Ohashi Y, Okamura M, Katayama R, Akinobu T, Shan AM, Yoshimatsu K, et al. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. Oncotarget. 2018;9:1641–55.
pubmed: 29416720
doi: 10.18632/oncotarget.22895
Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3:802–8.
pubmed: 11533659
doi: 10.1038/ncb0901-802
Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005;7:575–89.
pubmed: 15950906
doi: 10.1016/j.ccr.2005.05.007
Wang YN, Wang H, Yamaguchi H, Lee HJ, Lee HH, Hung MC. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem Biophys Res Commun. 2010;399:498–504.
pubmed: 20674546
pmcid: 2935258
doi: 10.1016/j.bbrc.2010.07.096
Klaver E, Zhao P, May M, Flanagan-Steet H, Freeze HH, Gilmore R, et al. Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing. Dis Model Mech. 2019;12:dmm039602.
pubmed: 31101650
pmcid: 6602306
doi: 10.1242/dmm.039602
Ostrander GK, Scribner N, Rohrschneider LR. Inhibition of v-fms-induced Tumor Growth in Nude Mice by Castanospermine. Cancer Res. 1988;48:1091–4.
pubmed: 3124955
Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 2008;68:3803–9.
pubmed: 18483264
pmcid: 3696581
doi: 10.1158/0008-5472.CAN-07-6389
Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res. 2010;16:3205–14.
pubmed: 20413434
pmcid: 3413408
doi: 10.1158/1078-0432.CCR-09-3331
Lopez-Sambrooks C, Shrimal S, Khodier C, Flaherty DP, Rinis N, Charest JC, et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol. 2016;12:1023–30.
pubmed: 27694802
pmcid: 5393272
doi: 10.1038/nchembio.2194
Lopez Sambrooks C, Baro M, Quijano A, Narayan A, Cui W, Greninger P, et al. Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018;78:5094–106.
pubmed: 30026325
doi: 10.1158/0008-5472.CAN-18-0505
Baro M, Lopez Sambrooks C, Quijano A, Saltzman WM, Contessa J. Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. Clin Cancer Res. 2019;25:784–95.
pubmed: 29967251
doi: 10.1158/1078-0432.CCR-18-0792
Dance M, Montagner A, Salles JP, Yart A, Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal. 2008;20:453–9.
pubmed: 17993263
doi: 10.1016/j.cellsig.2007.10.002
Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016;535:148–52.
pubmed: 27362227
doi: 10.1038/nature18621
Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 2004;5:1165–70.
pubmed: 15568014
pmcid: 1299195
doi: 10.1038/sj.embor.7400300
Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J, Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett. 2006;104:146–55.
pubmed: 16384610
doi: 10.1016/j.imlet.2005.11.018
Wang L, Jiang J, Zhang L, Zhang Q, Zhou J, Li L, et al. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. J Med Chem. 2020;63:1281–97.
pubmed: 31935086
doi: 10.1021/acs.jmedchem.9b01659